A patient developed rheumatoid arthritis three months after starting CGRP antibody therapy for migraines, raising questions about potential autoimmune triggering.
RA onset at 3 monthsRheumatoid arthritis developed 3 months after starting CGRP antibody therapy, with positive autoimmune markers
What the researchers found
A patient developed rheumatoid arthritis three months after starting CGRP antibody therapy for migraines, suggesting potential autoimmune triggering as an adverse effect.
Why it matters
CGRP antibodies are widely prescribed for migraine prevention. If they can trigger autoimmune conditions in susceptible individuals, this would be an important safety consideration.
The numbers in context
56-year-old woman, fremanezumab 225 mg monthly, symptoms emerged at 3 months. Lab tests showed elevated inflammatory markers and positive anti-CCP antibodies.
How the study worked
Single case report with clinical examination, laboratory tests, and autoimmune marker analysis.
Who was studied
56-year-old woman with severe migraines treated with fremanezumab
What this study cannot tell us
This is a single case report. Temporal association does not prove causation. The patient may have been developing RA independently.
How to read the evidence
Rated preliminary: single case report. Temporal association does not prove that fremanezumab caused the rheumatoid arthritis.
When this study was published
Published in 2024. Adds to a small but growing number of case reports linking CGRP blockade to autoimmune events.
The bigger picture
CGRP has immunomodulatory roles beyond pain signaling. Blocking it long-term could theoretically unmask autoimmune disease in genetically susceptible people, though a single case cannot prove causation.
Questions still open
- Should patients with autoimmune risk factors be monitored more closely on CGRP drugs?
- Does CGRP blockade increase autoimmune risk population-wide or only in susceptible individuals?
Common questions
Can CGRP migraine drugs cause autoimmune disease?
Should I be worried about CGRP drugs and autoimmunity?
Read the original research
Could CGRP mAbs for migraine trigger rheumatoid arthritis? Insights from a case report.
ARP rheumatology, 3(4), 337-338
Citation
Rua, Catarina; Beirão, Tiago; Silva, Catarina; Meirinhos, Tiago; Pinto, Patricia; Vieira, Romana; Aleixo-Santos, Joana; Costa, Flávio; Fonseca, Diogo; Pinto, Ana Sofia; Samões, Beatriz; Videira, Taciana. (2024). Could CGRP mAbs for migraine trigger rheumatoid arthritis? Insights from a case report.. ARP rheumatology, 3(4), 337-338. https://doi.org/10.63032/LZFI4171